Therapeutic potential of oleic acid supplementation in myotonic dystrophy muscle cell models.
Fatty acid
MSI2
Myoblast differentiation
Oleic acid
SCD1
miR-7
Journal
Biological research
ISSN: 0717-6287
Titre abrégé: Biol Res
Pays: England
ID NLM: 9308271
Informations de publication
Date de publication:
17 May 2024
17 May 2024
Historique:
received:
14
06
2023
accepted:
05
04
2024
medline:
18
5
2024
pubmed:
18
5
2024
entrez:
17
5
2024
Statut:
epublish
Résumé
We recently reported that upregulation of Musashi 2 (MSI2) protein in the rare neuromuscular disease myotonic dystrophy type 1 contributes to the hyperactivation of the muscle catabolic processes autophagy and UPS through a reduction in miR-7 levels. Because oleic acid (OA) is a known allosteric regulator of MSI2 activity in the biogenesis of miR-7, here we sought to evaluate endogenous levels of this fatty acid and its therapeutic potential in rescuing cell differentiation phenotypes in vitro. In this work, four muscle cell lines derived from DM1 patients were treated with OA for 24 h, and autophagy and muscle differentiation parameters were analyzed. We demonstrate a reduction of OA levels in different cell models of the disease. OA supplementation rescued disease-related phenotypes such as fusion index, myotube diameter, and repressed autophagy. This involved inhibiting MSI2 regulation of direct molecular target miR-7 since OA isoschizomer, elaidic acid (EA) could not cause the same rescues. Reduction of OA levels seems to stem from impaired biogenesis since levels of the enzyme stearoyl-CoA desaturase 1 (SCD1), responsible for converting stearic acid to oleic acid, are decreased in DM1 and correlate with OA amounts. For the first time in DM1, we describe a fatty acid metabolism impairment that originated, at least in part, from a decrease in SCD1. Because OA allosterically inhibits MSI2 binding to molecular targets, reduced OA levels synergize with the overexpression of MSI2 and contribute to the MSI2 > miR-7 > autophagy axis that we proposed to explain the muscle atrophy phenotype.
Sections du résumé
BACKGROUND
BACKGROUND
We recently reported that upregulation of Musashi 2 (MSI2) protein in the rare neuromuscular disease myotonic dystrophy type 1 contributes to the hyperactivation of the muscle catabolic processes autophagy and UPS through a reduction in miR-7 levels. Because oleic acid (OA) is a known allosteric regulator of MSI2 activity in the biogenesis of miR-7, here we sought to evaluate endogenous levels of this fatty acid and its therapeutic potential in rescuing cell differentiation phenotypes in vitro. In this work, four muscle cell lines derived from DM1 patients were treated with OA for 24 h, and autophagy and muscle differentiation parameters were analyzed.
RESULTS
RESULTS
We demonstrate a reduction of OA levels in different cell models of the disease. OA supplementation rescued disease-related phenotypes such as fusion index, myotube diameter, and repressed autophagy. This involved inhibiting MSI2 regulation of direct molecular target miR-7 since OA isoschizomer, elaidic acid (EA) could not cause the same rescues. Reduction of OA levels seems to stem from impaired biogenesis since levels of the enzyme stearoyl-CoA desaturase 1 (SCD1), responsible for converting stearic acid to oleic acid, are decreased in DM1 and correlate with OA amounts.
CONCLUSIONS
CONCLUSIONS
For the first time in DM1, we describe a fatty acid metabolism impairment that originated, at least in part, from a decrease in SCD1. Because OA allosterically inhibits MSI2 binding to molecular targets, reduced OA levels synergize with the overexpression of MSI2 and contribute to the MSI2 > miR-7 > autophagy axis that we proposed to explain the muscle atrophy phenotype.
Identifiants
pubmed: 38760841
doi: 10.1186/s40659-024-00496-z
pii: 10.1186/s40659-024-00496-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Subventions
Organisme : Ministerio de Ciencia e Innovación
ID : RTI2018-094599-B-100
Organisme : Ministerio de Ciencia e Innovación
ID : PRE2019-090622
Organisme : Conselleria de Cultura, Educación y Ciencia, Generalitat Valenciana
ID : PROMETEO/2020/081
Organisme : Instituto de Salud Carlos III
ID : PI21/00311
Organisme : Instituto de Salud Carlos III
ID : CD21/00031
Informations de copyright
© 2024. The Author(s).
Références
Johnson NE, Butterfield RJ, Mayne K, Newcomb T, Imburgia C, Dunn D et al. Population Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of State-wide Blood Screening Program. Neurology. 2021;10.1212/WNL.0000000000011425.
Smith CA, Gutmann L. Myotonic dystrophy type 1 management and therapeutics. Curr Treat Options Neurol. 2016;18(12):52.
pubmed: 27826760
doi: 10.1007/s11940-016-0434-1
André LM, Ausems CRM, Wansink DG, Wieringa B. Abnormalities in skeletal muscle myogenesis, growth, and regeneration in myotonic dystrophy. Front Neurol. 2018;9.
Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, Thornton CA, et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000;19(17):4439–48.
pubmed: 10970838
pmcid: 302046
doi: 10.1093/emboj/19.17.4439
Konieczny P, Stepniak-Konieczna E, Sobczak K. MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res. 2014;42(17):10873–87.
pubmed: 25183524
pmcid: 4176163
doi: 10.1093/nar/gku767
Batra R, Charizanis K, Manchanda M, Mohan A, Li M, Finn DJ, et al. Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease. Mol Cell 2014/09/30. 2014;56(2):311–22.
doi: 10.1016/j.molcel.2014.08.027
Jones K, Wei C, Iakova P, Bugiardini E, Schneider-Gold C, Meola G et al. GSK3beta mediates muscle pathology in myotonic dystrophy. J Clin Invest. 2012/11/20. 2012;122(12):4461–72.
Wei C, Stock L, Valanejad L, Zalewski ZA, Karns R, Puymirat J, et al. Correction of GSK3beta at young age prevents muscle pathology in mice with myotonic dystrophy type 1. FASEB J. 2018;32(4):2073–85.
pubmed: 29203592
pmcid: 5893173
doi: 10.1096/fj.201700700R
Gladman JT, Yadava RS, Mandal M, Yu Q, Kim YK, Mahadevan MS. NKX2-5, a modifier of skeletal muscle pathology due to RNA toxicity. Hum Mol Genet. 2014/08/30. 2015;24(1):251–64.
Brockhoff M, Rion N, Chojnowska K, Wiktorowicz T, Eickhorst C, Erne B et al. Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I. J Clin Invest. 2017/01/10. 2017;127(2):549–63.
Ravel-Chapuis A, Al-Rewashdy A, Bélanger G, Jasmin BJ. Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles. Hum Mol Genet. 2018;27(19):3361–76.
pubmed: 29982462
pmcid: 6140770
doi: 10.1093/hmg/ddy245
Wang GS, Kuyumcu-Martinez MN, Sarma S, Mathur N, Wehrens XH, Cooper TA. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest. 2009/11/13. 2009;119(12):3797–806.
Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 2007/10/16. 2007;28(1):68–78.
doi: 10.1016/j.molcel.2007.07.027
Bargiela A, Cerro-Herreros E, Fernandez-Costa JM, Vilchez JJ, Llamusi B, Artero R. Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 Drosophila model. DMM Disease Models Mech. 2015;8(7):679–90.
doi: 10.1242/dmm.018127
Bargiela A, Sabater-Arcis M, Espinosa-Espinosa J, Zulaica M, Lopez de Munain A, Artero R. Increased muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models. Proc Natl Acad Sci. 2019;116(50):25203–13.
pubmed: 31754023
pmcid: 6911202
doi: 10.1073/pnas.1820297116
Sabater-Arcis M, Bargiela A, Furling D, Artero R. miR-7 restores phenotypes in myotonic dystrophy muscle cells by repressing Hyperactivated Autophagy. Mol Therapy: Nucleic Acid. 2020;19:278–92.
Morriss GR, Rajapakshe K, Huang S, Coarfa C, Cooper TA. Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1. Hum Mol Genet. 2018;27(16):2789–804.
pubmed: 29771332
pmcid: 6077786
doi: 10.1093/hmg/ddy192
Loro E, Rinaldi F, Malena A, Masiero E, Novelli G, Angelini C, et al. Normal myogenesis and increased apoptosis in myotonic dystrophy type-1 muscle cells. Cell Death Differ 2010/05/01. 2010;17(8):1315–24.
doi: 10.1038/cdd.2010.33
Gu DN, Jiang MJ, Mei Z, Dai JJ, Dai CY, Fang C, et al. microRNA-7 impairs autophagy-derived pools of glucose to suppress pancreatic cancer progression. Cancer Lett. 2017;400:69–78. 2017/04/30.
pubmed: 28450156
doi: 10.1016/j.canlet.2017.04.020
Choudhury NR, de Lima Alves F, de Andres-Aguayo L, Graf T, Caceres JF, Rappsilber J et al. Tissue-specific control of brain-enriched miR-7 biogenesis. Genes Dev. 2013/01/12. 2013;27(1):24–38.
Sabater-Arcis M, Bargiela A, Moreno N, Poyatos-Garcia J, Vilchez JJ, Artero R. Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through miR-7 biogenesis repression. Mol Ther Nucleic Acids. 2021;25:652–67.
pubmed: 34589284
pmcid: 8463325
doi: 10.1016/j.omtn.2021.08.010
Kumar S, Downie Ruiz Velasco A, Michlewski G. Oleic Acid Induces MiR-7 Processing through Remodeling of Pri-MiR-7/Protein Complex. J Mol Biol. 2017/05/10. 2017;429(11):1638–49.
Karacor K, Cam M. Effects of oleic acid. Med Sci Discovery. 2015;2(1):125.
doi: 10.36472/msd.v2i1.53
Sales-Campos H, Reis de Souza P, Crema Peghini B, Santana da Silva J, Ribeiro Cardoso C. An overview of the Modulatory effects of oleic acid in Health and Disease. Mini Rev Med Chem. 2013;13(2):201–10.
pubmed: 23278117
Duarte MKRN, de Araújo JNG, Duarte VHR, de Oliveira KM, de Oliveira JM, Carioca AAF, et al. The relationship of the oleic acid level and ECHDC3 mRNA expression with the extent of coronary lesion. Lipids Health Dis. 2016;15(1):144.
pubmed: 27586541
pmcid: 5009642
doi: 10.1186/s12944-016-0312-6
Wang Q, Liu R, Chang M, Zhang H, Jin Q, Wang X. Dietary oleic acid supplementation and blood inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2022;62(9):2508–25.
pubmed: 33305589
doi: 10.1080/10408398.2020.1854673
Abreu P, Pinheiro CHJ, Vitzel KF, Vasconcelos DAA, Torres RP, Fortes MS, et al. Contractile function recovery in severely injured gastrocnemius muscle of rats treated with either oleic or linoleic acid. Exp Physiol. 2016;101(11):1392–405.
pubmed: 27579497
doi: 10.1113/EP085899
Watanabe N, Komiya Y, Sato Y, Watanabe Y, Suzuki T, Arihara K. Oleic acid up-regulates myosin heavy chain (MyHC) 1 expression and increases mitochondrial mass and maximum respiration in C2C12 myoblasts. Biochem Biophys Res Commun. 2020;525(2):406–11.
pubmed: 32093891
doi: 10.1016/j.bbrc.2020.02.099
Zhang G, Chen X, Lin L, Wen C, Rao S. [Effects of fatty acids on proliferation and differentiation of myoblast]. Wei Sheng Yan Jiu. 2012;41(6):883–8.
pubmed: 23424861
Lipina C, Hundal HS. Lipid modulation of skeletal muscle mass and function. J Cachexia Sarcopenia Muscle. 2017;8(2):190–201.
pubmed: 27897400
doi: 10.1002/jcsm.12144
Abreu P, Leal-Cardoso JH, Ceccatto VM, Hirabara SM. Regulation of muscle plasticity and trophism by fatty acids: a short review. Rev Assoc Med Bras. 2017;63(2):148–55.
pubmed: 28355376
doi: 10.1590/1806-9282.63.02.148
Hurley MS, Flux C, Salter AM, Brameld JM. Effects of fatty acids on skeletal muscle cell differentiation in vitro. Br J Nutr. 2006;95(3):623–30.
pubmed: 16512949
doi: 10.1079/BJN20051711
Lee JH, Tachibana H, Morinaga Y, Fujimura Y, Yamada K. Modulation of proliferation and differentiation of C2C12 skeletal muscle cells by fatty acids. Life Sci. 2009;84(13–14):415–20.
pubmed: 19302823
doi: 10.1016/j.lfs.2009.01.004
Tan Y, Jin Y, Zhao P, Wu J, Ren Z. Lipid droplets contribute myogenic differentiation in C2C12 by promoting the remodeling of the acstin-filament. Cell Death Dis. 2021;12(12):1102.
pubmed: 34815388
pmcid: 8611090
doi: 10.1038/s41419-021-04273-8
Arandel L, Polay Espinoza M, Matloka M, Bazinet A, De Dea Diniz D, Naouar N et al. Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds. Dis Model Mech. 2017/02/12. 2017;10(4):487–97.
Rodríguez-Arribas M, Pizarro-Estrella E, Gómez-Sánchez R, Yakhine-Diop SMS, Gragera-Hidalgo A, Cristo A, et al. IFDOTMETER J Lab Autom. 2016;21(2):246–59.
pubmed: 26303944
doi: 10.1177/2211068215600650
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-∆∆CT method. Methods. 2001;25(4):402–8.
pubmed: 11846609
doi: 10.1006/meth.2001.1262
Zhou L, Sheng W, Jia C, Shi X, Cao R, Wang G, et al. Musashi2 promotes the progression of pancreatic cancer through a novel ISYNA1-p21/ZEB‐1 pathway. J Cell Mol Med. 2020;24(18):10560–72.
pubmed: 32779876
pmcid: 7521282
doi: 10.1111/jcmm.15676
Zhang H, Tan S, Wang J, Chen S, Quan J, Xian J, et al. Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway. Exp Cell Res. 2014;320(1):119–27.
pubmed: 24076374
doi: 10.1016/j.yexcr.2013.09.009
Tanida I, Ueno T, Kominami E. In. LC3 and Autophagy. 2008. p. 77–88.
Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T. Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol. 2009/02/10. 2009;452:181–97.
Rusten TE, Stenmark H. p62, an autophagy hero or culprit? Nat Cell Biol 2010/03/02. 2010;12(3):207–9.
doi: 10.1038/ncb0310-207
Chal J, Pourquié O. Making muscle: skeletal myogenesis in vivo and in vitro. Development. 2017;144(12):2104–22.
pubmed: 28634270
doi: 10.1242/dev.151035
Mensink RP. Metabolic and health effects of isomeric fatty acids. Curr Opin Lipidol. 2005;16(1):27–30.
pubmed: 15650560
doi: 10.1097/00041433-200502000-00006
Clingman CC, Deveau LM, Hay SA, Genga RM, Shandilya SM, Massi F et al. Allosteric inhibition of a stem cell RNA-binding protein by an intermediary metabolite. Elife. 2014/06/18. 2014;3.
Kumar S, Downie Ruiz Velasco A, Michlewski G. Oleic Acid Induces MiR-7 Processing through Remodeling of Pri-MiR-7/Protein Complex. J Mol Biol [Internet]. 2017/05/10. 2017;429(11):1638–49. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=28483648
Yeh DW, Zhao X, Siddique HR, Zheng M, Choi HY, Machida T, et al. MSI2 promotes translation of multiple IRES-containing oncogenes and virus to induce self-renewal of tumor initiating stem-like cells. Cell Death Discov. 2023;9(1):141.
pubmed: 37117191
pmcid: 10147607
doi: 10.1038/s41420-023-01427-9
Lim JH, Gerhart-Hines Z, Dominy JE, Lee Y, Kim S, Tabata M, et al. Oleic acid stimulates complete oxidation of fatty acids through protein kinase A-dependent activation of SIRT1-PGC1α complex. J Biol Chem. 2013;288(10):7117–26.
pubmed: 23329830
pmcid: 3591621
doi: 10.1074/jbc.M112.415729
Shao F, Ford DA. Elaidic Acid increases hepatic lipogenesis by Mediating Sterol Regulatory Element Binding Protein-1c activity in HuH‐7 cells. Lipids. 2014;49(5):403–13.
pubmed: 24481861
pmcid: 3999188
doi: 10.1007/s11745-014-3883-x
Granados N, Amengual J, Ribot J, Palou A, Luisa Bonet M. Distinct effects of oleic acid and its trans -isomer elaidic acid on the expression of myokines and adipokines in cell models. Br J Nutr. 2011;105(8):1226–34.
pubmed: 21208487
doi: 10.1017/S0007114510004885
Piccinin E, Cariello M, De Santis S, Ducheix S, Sabbà C, Ntambi JM, et al. Role of oleic acid in the Gut-Liver Axis: from Diet to the regulation of its synthesis via Stearoyl-CoA desaturase 1 (SCD1). Nutrients. 2019;11(10):2283.
pubmed: 31554181
pmcid: 6835877
doi: 10.3390/nu11102283
Yao DW, Luo J, He QY, Xu HF, Li J, Shi HB, et al. Liver X receptor α promotes the synthesis of monounsaturated fatty acids in goat mammary epithelial cells via the control of stearoyl-coenzyme A desaturase 1 in an SREBP-1-dependent manner. J Dairy Sci. 2016;99(8):6391–402.
pubmed: 27209141
doi: 10.3168/jds.2016-10990
Piccinin E, Cariello M, Moschetta A. Lipid metabolism in colon cancer: role of Liver X receptor (LXR) and Stearoyl-CoA desaturase 1 (SCD1). Mol Aspects Med. 2021;78:100933.
pubmed: 33218679
doi: 10.1016/j.mam.2020.100933
Wang B, Tontonoz P. Liver X receptors in lipid signalling and membrane homeostasis. Nat Rev Endocrinol. 2018;14(8):452–63.
pubmed: 29904174
pmcid: 6433546
doi: 10.1038/s41574-018-0037-x
Amtul Z, Westaway D, Cechetto DF, Rozmahel RF. Oleic acid ameliorates amyloidosis in Cellular and Mouse models of Alzheimer’s Disease. Brain Pathol. 2011;21(3):321–9.
pubmed: 21040071
doi: 10.1111/j.1750-3639.2010.00449.x
Perdomo L, Beneit N, Otero YF, Escribano Ó, Díaz-Castroverde S, Gómez-Hernández A, et al. Protective role of oleic acid against cardiovascular insulin resistance and in the early and late cellular atherosclerotic process. Cardiovasc Diabetol. 2015;14(1):75.
pubmed: 26055507
pmcid: 4475625
doi: 10.1186/s12933-015-0237-9
Navarro-Tito N, Soto-Guzman A, Castro-Sanchez L, Martinez-Orozco R, Salazar EP. Oleic acid promotes migration on MDA-MB-231 breast cancer cells through an arachidonic acid-dependent pathway. Int J Biochem Cell Biol. 2010;42(2):306–17.
pubmed: 19931412
doi: 10.1016/j.biocel.2009.11.010
Search of. oleic acid - List Results - ClinicalTrials.gov [Internet]. [cited 2023 May 29]. https://clinicaltrials.gov/ct2/results?cond=&term=oleic+acid&cntry=&state=&city=&dist =.
Stevenson J, Huang EY, Olzmann JA. Endoplasmic reticulum–Associated degradation and lipid homeostasis. Annu Rev Nutr. 2016;36(1):511–42.
pubmed: 27296502
pmcid: 6268005
doi: 10.1146/annurev-nutr-071715-051030
Pinheiro CH. da J. Efeito da terapia com células-tronco musculares e células-tronco mesenquimais na regeneração do músculo esquelético: modulação por ácido oléico. [São Paulo]: Universidade de São Paulo; 2012.
Vignaud A, Ferry A, Huguet A, Baraibar M, Trollet C, Hyzewicz J, et al. Progressive skeletal muscle weakness in transgenic mice expressing CTG expansions is associated with the activation of the ubiquitin-proteasome pathway. Neuromuscul Disord 2010/03/30. 2010;20(5):319–25.
doi: 10.1016/j.nmd.2010.03.006
Huguet A, Medja F, Nicole A, Vignaud A, Guiraud-Dogan C, Ferry A, et al. Molecular, Physiological, and Motor Performance Defects in DMSXL Mice Carrying >1,000 CTG Repeats from the Human DM1 Locus. Pearson CE, editor. PLoS Genet. 2012 Nov 29;8(11):e1003043.
Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, et al. Ensembl 2022. Nucleic Acids Res. 2022;50(D1):D988–95.
pubmed: 34791404
doi: 10.1093/nar/gkab1049
Nieuwenhuis S, Okkersen K, Widomska J, Blom P, ’t Hoen PAC, van Engelen B et al. Insulin Signaling as a key moderator in myotonic dystrophy type 1. Front Neurol. 2019;10.
López-Martínez A, Soblechero-Martín P, De-la-Puente-Ovejero L, Nogales-Gadea G, Arechavala-Gomeza V. An overview of alternative splicing defects implicated in myotonic dystrophy type I. Genes (Basel). 2020;11(9):1109.
pubmed: 32971903
doi: 10.3390/genes11091109
Rakocevic Stojanovic V, Peric S, Lavrnic D, Popovic S, Ille T, Stevic Z, et al. Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. Acta Neurol Scand. 2010;121(2):94–8.
pubmed: 19804472
doi: 10.1111/j.1600-0404.2009.01237.x
SUZUKI H. Hyperglucagonemia in myotonic dystrophy. J Clin Endocrinol Metab. 1981;52(4):790–5.
pubmed: 7009630
doi: 10.1210/jcem-52-4-790
Mauvoisin D, Rocque G, Arfa O, Radenne A, Boissier P, Mounier C. Role of the PI3-kinase/mTor pathway in the regulation of the stearoyl CoA desaturase (SCD1) gene expression by insulin in liver. J Cell Commun Signal. 2007;1(2):113–25.
pubmed: 18481202
pmcid: 2275876
doi: 10.1007/s12079-007-0011-1
Casimir DA, Ntambi JM. cAMP activates the expression of Stearoyl-CoA desaturase gene 1 during early preadipocyte differentiation. J Biol Chem. 1996;271(47):29847–53.
pubmed: 8939924
doi: 10.1074/jbc.271.47.29847
Mauvoisin D, Prévost M, Ducheix S, Arnaud MP, Mounier C. Key role of the ERK1/2 MAPK pathway in the transcriptional regulation of the Stearoyl-CoA desaturase (SCD1) gene expression in response to leptin. Mol Cell Endocrinol. 2010;319(1–2):116–28.
pubmed: 20109524
doi: 10.1016/j.mce.2010.01.027
Lefevre P, Diot C, Legrand P, Douaire M. Hormonal regulation of Stearoyl Coenzyme-A desaturase 1 activity and gene expression in primary cultures of Chicken hepatocytes. Arch Biochem Biophys. 1999;368(2):329–37.
pubmed: 10441384
doi: 10.1006/abbi.1999.1315
Ozimski LL, Sabater-Arcis M, Bargiela A, Artero R. The hallmarks of myotonic dystrophy type 1 muscle dysfunction. Biol Rev. 2020;brv.12674.
Costa A, Cruz AC, Martins F, Rebelo S. Protein phosphorylation alterations in myotonic dystrophy type 1: a systematic review. Int J Mol Sci. 2023;24(4):3091.
pubmed: 36834509
pmcid: 9965115
doi: 10.3390/ijms24043091
Chen G, Liang G, Ou J, Goldstein JL, Brown MS. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proceedings of the National Academy of Sciences. 2004;101(31):11245–50.
Liu Y, Tang C. Regulation of ABCA1 functions by signaling pathways. Biochim et Biophys Acta (BBA) - Mol Cell Biology Lipids. 2012;1821(3):522–9.
Song H, Yang R, Zhang J, Sun P, Xing X, Wang L, et al. Oleic acid-induced steatosis model establishment in LMH cells and its effect on lipid metabolism. Poult Sci. 2023;102(1):102297.
pubmed: 36446267
doi: 10.1016/j.psj.2022.102297
Briolay A, Jaafar R, Nemoz G, Bessueille L. Myogenic differentiation and lipid-raft composition of L6 skeletal muscle cells are modulated by PUFAs. Biochim Biophys Acta. 2013;1828(2):602–13.
pubmed: 23079583
doi: 10.1016/j.bbamem.2012.10.006
Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016;42:63–71.
pubmed: 27156098
doi: 10.1016/j.dnarep.2016.04.008
Gonzalez-Barriga A, Kranzen J, Croes HJ, Bijl S, van den Broek WJ, van Kessel ID et al. Cell membrane integrity in myotonic dystrophy type 1: implications for therapy. PLoS One. 2015/03/24. 2015;10(3):e0121556.
Lopez S, Bermudez B, Montserrat-de la Paz S, Jaramillo S, Varela LM, Ortega-Gomez A, et al. Membrane composition and dynamics: a target of bioactive virgin olive oil constituents. Biochimica et Biophysica Acta (BBA). - Biomembr. 2014;1838(6):1638–56.
doi: 10.1016/j.bbamem.2014.01.007
Bourre JM, Dumont O, Durand G. Dose-effect of dietary oleic acid: oleic acid is conditionally essential for some organs. Reprod Nutr Dev. 2004;44(4):371–80.
pubmed: 15535469
doi: 10.1051/rnd:2004042